Results 281 to 290 of about 81,753 (307)

[Development of HDAC inhibitors].

Gan to kagaku ryoho. Cancer & chemotherapy, 2010
In the mechanisms of carcinogenesis, it is becoming apparent that not only genetic abnormalities including DNA mutations, but also epigenetic abnormalities are heavily involved. Simultaneously, certain kinds of compounds indicated anti-tumor activity through their epigenetic effects.
openaire   +1 more source

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly  

HDAC Inhibitors

2011
openaire   +2 more sources

Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea

Ca-A Cancer Journal for Clinicians, 2018
Clement Chung
exaly  

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

Nature, 2020
Ugur Sahin, Petra Oehm, Mathias Vormehr
exaly  

Lung cancer: New biological insights and recent therapeutic advances

Ca-A Cancer Journal for Clinicians, 2011
Suresh S Ramalingam, Fadlo R Khuri
exaly  

HDAC Inhibitors

2017
openaire   +1 more source

HDAC Inhibitors

2012
openaire   +1 more source

NTRK fusion-positive cancers and TRK inhibitor therapy

Nature Reviews Clinical Oncology, 2018
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon   +2 more
exaly  

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Nature Reviews Cancer, 2019
Jonathan J Havel, Diego Chowell, Timothy A Chan   +2 more
exaly